Drugs / Marzeptacog Alfa (Activated)
Marzeptacog Alfa (Activated)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01439971 | Dec 2011 → Oct 2015 | hemophilia A | Catalyst Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03407651 | Dec 2017 → Mar 2019 | hemophilia A, hemophilia B | Catalyst Biosciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Marzeptacog Alfa (Activated) | “Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of a Daily Subcutaneous Treatment Regimen With Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in...” NCT03407651 ↗ |
| Known as | 813d | “An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics/Pharmacodynamics Of Pf-05280602, A Recombinant Factor Viia Variant (813d), In Adult...” NCT01439971 ↗ |
| Known as | PF-05280602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01439971 ↗ |
| Modality | Protein / enzyme biologic | “A Recombinant Factor Viia Variant (813d)” NCT01439971 ↗ |
| Route | Intravenous | “IV infusion” NCT01439971 ↗ |